HOME >> MEDICINE >> NEWS
Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years

THOUSAND OAKS, Calif., November 13, 2006 -- Amgen (NASDAQ: AMGN), today announced that data from an ongoing open-label, multinational, phase 4 extension study showed that patients with ankylosing spondylitis (AS) who received treatment with Enbrel? (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy. These results are consistent with an ENBREL phase 3 clinical trial at 24 weeks. The 160-week results will be presented at the American College of Rheumatology (ACR) Scientific Meeting in Washington, D.C.

"These data demonstrate that ENBREL can provide substantial long-term improvement in AS symptoms such as total back pain and spinal mobility," said Joachim Sieper, M.D., professor of rheumatology, Charite University in Berlin, Germany. "Because AS is a chronic inflammatory disease that requires ongoing management, it is important to offer patients a treatment option that is effective, has an established safety profile, and can be used over the long-term."

Data presented at ACR showed that 59 patients who received open-label ENBREL treatment for up to 160 weeks experienced sustained clinical improvements. Overall, 78 percent of patients (n=46) continuing treatment with ENBREL achieved a 20 percent improvement in the Assessment on Ankylosing Spondylitis Response Criteria (ASAS 20) after 160 weeks of treatment. ASAS is a composite measure of improvement in AS symptoms that include total back pain, patient assessment of disease activity, inflammation and physical function. Thirty-one percent of patients (n= 18) achieved partial remission at week 160. Partial remission, as defined by ASAS, is a low disease activity level (score < 20 units out of 100 in each of the four ASAS criteria).

Additional ENBREL data presented at ACR from this phase 4 extension study show that improvement in spinal mobility was also sustained through 148 to 160 weeks of
'"/>

Contact: Sonia Fiorenza
805-447-1604
Porter Novelli
13-Nov-2006


Page: 1 2 3

Related medicine news :

1. Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate
2. Sports concussion research using fMRI provides insight for safe return-to-play decisions
3. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer
4. Daytrana provides significant effectiveness in both boys and girls with ADHD
5. New book provides unprecedented look at role of religion over a lifetime
6. New edition of medical reference book provides the latest in hematology
7. Lung cancer screening regimen provides opportunity for cure
8. MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy
9. IceSAR campaign provides glimpse of future Sentinel-1 images over ice
10. Darunavir with FUZEON provides HIV patients a better chance to reach undetectable viral load
11. Optical technique provides improved virtual biopsies of internal surfaces

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... ... March 29, 2017 , ... The assembly ... assembly protocols involve many repetitive steps and often scientists require many different versions ... high-throughput needed, and results in a lower error rate and cost saving for ...
(Date:3/29/2017)... , ... March 29, 2017 ... ... and South Hills of Pittsburgh now have easier access to the robotic-assisted ... by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson ...
(Date:3/29/2017)... ... ... AvePoint , the Microsoft Cloud expert, is pleased to announce the ... the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ceremony ... Mayor of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more than ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is the annual ... the Diabetes Risk Test to find out if they are at risk for developing ... light up the evening sky by programming the LAX pylons the color red. Downtown’s ...
(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017  Spiral Therapeutics, Inc. today ... Bionure Farma, S.L. for the worldwide exclusive rights ... in the field of otolaryngology for aggregate payments ... The agreement provides Spiral with the option ... differentiated product profile. Under the terms of the ...
(Date:3/29/2017)... 2017   Dynatronics Corporation (NASDAQ: ... Cynthia L. McHenry (Cyndi) as Vice ... leading Dynatronics manufacturing, distribution, and purchasing operations across ... CEO Kelvyn H. Cullimore, Jr. ... process conducted by the company as it continues ...
(Date:3/29/2017)... SILVER SPRING, Md. , March 29, 2017 On ... Ocrevus (ocrelizumab) to treat adult patients with relapsing forms ... (PPMS). This is the first drug approved by the ... by a health care professional.  "Multiple ... life," said Billy Dunn , M.D., director of ...
Breaking Medicine Technology:
Cached News: